Everolimus for Advanced Pancreatic Neuroendocrine Tumors

20112,831 citationsJournal Articlegreen Open Access

Authors

James C. Yao · The University of Texas MD Anderson Cancer Center

Manisha H. Shah · The Ohio State University

Tetsuhide Ito · Kyushu University

C. Lombard Bohas · Hôpital Edouard Herriot

Edward M. Wolin · Cedars-Sinai Medical Center

Eric Van Cutsem · KU Leuven

Timothy J. Hobday ·

Abstract

Everolimus, as compared with placebo, significantly prolonged progression-free survival among patients with progressive advanced pancreatic neuroendocrine tumors and was associated with a low rate of severe adverse events. (Funded by Novartis Oncology; RADIANT-3 ClinicalTrials.gov number, NCT00510068.).

Topics & Keywords

Neuroendocrine Tumor Research Advances Lung Cancer Research Studies Gestational Trophoblastic Disease Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 364, Issue 6, pp. 514-523

DOI: 10.1056/nejmoa1009290

Field-Weighted Citation Impact: 176.24